HOWARD C. GOODMAN, M.D.; SHELDON M. WOLFF, M.D.; ROBERT R. CARPENTER, M.D.; BURTON R. ANDERSEN, M.D.; MICHAEL W. BRANDRISS, M.D.
Dr. Howard C. Goodman: During the past 2 years, drugs which were developed for the chemotherapy of cancer and which function as antimetabolites have been administered to patients with non-neoplastic diseases. Enough remarkable remissions of these non-neoplastic diseases have occurred to indicate an interesting new development in medicine. The purpose of this conference is to review this development briefly and to present work which, although in progress, can already document both the clinical effectiveness and the toxicity of one of the purine antimetabolites, 6-thioguanine. We will also describe some experimental approaches designed to study the mechanism of action of the
GOODMAN HC, WOLFF SM, CARPENTER RR, et al. Current Studies on the Effect of Antimetabolites in Nephrosis, Other Non-Neoplastic Diseases, and Experimental Animals: Combined Clinical Staff Conference at the National Institutes of Health. Ann Intern Med. 1963;59:388–407. doi: https://doi.org/10.7326/0003-4819-59-3-388
Download citation file:
Published: Ann Intern Med. 1963;59(3):388-407.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use